RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Gilead announces EMA CHMP positive opinion for HIV-1 drug, Eviplera

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera.

23 Sep 2011

NIH honors Utah biochemist with Pioneer Award for dsRNA research

University of Utah biochemist Brenda L. Bass, Ph.D., has dedicated her career to following the path less traveled.

23 Sep 2011

Families help identify new gene for motor neuron disease

Families suffering from a history of motor neuron disease have helped an international scientific team locate a new gene linked to the incurable disease.

22 Sep 2011

Scientists discover new genetic mutation for amyotrophic lateral sclerosis

A team led by scientists from Johns Hopkins and the National Institutes of Health has discovered a new genetic mutation for amyotrophic lateral sclerosis (ALS) and a related disease called frontotemporal dementia (FTD) that appears to account for more than a third of all inherited cases of these diseases.

22 Sep 2011

Genetic differences play a role in prostate cancer disparities

Genetic differences in prostate cells seem to be a root cause of the prostate cancer disparities between African-American men and white men, according to findings presented at the Fourth AACR Conference on The Science of Cancer Health Disparities, held here Sept. 18-21, 2011.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

A code beyond DNA: Modified tRNA bases are characteristic of species

Our genetic code consists of four “letters” in the form of the nucleobases in our DNA and RNA. Three letters together form a “word” that are translated into an amino acid by tRNA and combined into proteins. Special markings subdivide the gene into active and inactive regions. A third possible level of information has so far received less attention: the chemical modification of tRNA nucleobases. In the journal Angewandte Chemie Thomas Carell and a team at the University of Munich have now demonstrated that tRNA modification profiles can be used for the characterization of species and the differentiation of pathogenic and nonpathogenic bacterial strains.

20 Sep 2011

Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective

Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.

20 Sep 2011

FoxM1 protein plays a critical role in development of medulloblastomas

Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available.

20 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Techulon signs distribution agreement with BioConcept for Glycofect

Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland.

19 Sep 2011

Hologic to showcase automated systems for cervical cancer screening at IPV, Berlin

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will focus on two new, ready-to-market automated options for cervical cancer screening at the International Papillomavirus Conference & Clinical Workshop (IPV) September 17th through 22nd in Berlin, Germany.

From Hologic, Inc. 17 Sep 2011

Silence receives U.S. patent entitled, 'Use of Protein Kinase N beta'

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office.

16 Sep 2011

New nanopore sensor can lead to early detection of lung cancer

When lung cancer strikes, it often spreads silently into more advanced stages before being detected. In a new article published in Nature Nanotechnology, biological engineers and medical scientists at the University of Missouri reveal how their discovery could provide a much earlier warning signal.

16 Sep 2011

Scientists uncover unknown fail-safe pathway for inherited disorders

Scientists at the University of California, San Diego School of Medicine have uncovered a previously unknown fail-safe (compensatory) pathway that potentially protects the brain and other organs from genetic and environmental threats.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

Axeq announces Turnkey Discovery sequencing and analysis services

Axeq Technologies announced the industry-first Axeq Turnkey Discovery analytical bioinformatic services coupled with high-coverage exome sequencing applications.

15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011